LifeMD Delays Q3 10-Q to Fix Revenue and Expense Recognition Errors
LFMD is trading near its 52-week low of $1.88 (5.3% above the low).
Summary
LifeMD is pushing back its Q3 2026 10-Q because it needs to correct revenue and expense recognition errors, and it is still evaluating how those errors affect its disclosure controls and internal control over financial reporting. That is an accounting problem, not a timing hiccup — revenue and expense recognition sit at the core of reported results, so prior-period numbers may not be reliable as stated. The company is already fragile: the last 10-Q showed a wider net loss and a breach of a debt covenant on its new $30 million credit facility. A delayed filing plus internal-control questions raises the risk of a restatement and adds pressure from lenders and auditors. Watch for the corrected figures and any 8-K or NT 10-Q that quantifies the impact.
At the time of this announcement, LFMD was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $95.4M. The 52-week trading range was $1.88 to $5.44. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.